College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
 
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
 
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Reference Resources and Publications > NewsPath > The Role of Cytogenetics in Pediatric Solid Tissue Tumors
Printable Version

  NewsPath®

 

The Role of Cytogenetics in Pediatric Solid Tissue Tumors

Posted April 23, 2008

Jennifer Laudadio, MD
CAP/ACMG Cytogenetics
Resource Committee

Tumors of infancy and childhood differ from adult tumors in both incidence and type. Aside from hematopoietic tumors, the most common pediatric neoplasms arise in nervous tissues, bones, soft tissues, and kidneys. Some examples of the most common neoplasms include neuroblastoma, Ewing’s sarcoma, rhabdomyosarcoma, and Wilms tumor. These tumors are often primitive appearing histologically and consist of small, round, blue cells. Due to the overlapping morphology, cytogenetic analysis can be very useful in establishing the diagnosis. Also, cytogenetic findings are frequently predictors of prognosis. Cytogenetic analysis is achieved through both traditional karyotype analysis and fluorescent in situ hybridization (FISH). Conventional cytogenetics requires fresh, unfixed tissue, whereas FISH can be performed on fresh, frozen, or paraffin-embedded tissue.

In neuroblastomas, cytogenetics has a key role in determining prognosis. The most common karyotypic abnormality is partial gain of 17q. This finding occurs in up to 50% of neuroblastomas and is frequently due to an unbalanced translocation.1 Gain of 17q is associated with poor prognosis as are deletions in the short arm of chromosome 1. Hyperdiploidy and triploidy are associated with a favorable prognosis. The most significant genetic prognostic predictor in neuroblastomas is MYCN amplification, and it is strongly associated with an adverse prognosis. Amplification can be seen on karyotype analysis as either double minutes (small accessory chromosomes) or homogeneously stained regions. However, FISH is the method more commonly performed to determine MYCN amplification status.

Soft tissue and bone tumors often times have characteristic translocations. These translocations can be detected by both FISH and karyotype analysis. Ewing’s sarcoma was the first sarcoma to be defined by a specific translocation.2 Ewing’s sarcoma is most commonly associated with t(11;22) resulting in a EWSR1/FLI1 gene fusion. This translocation will be detected in >90% of Ewing’s sarcomas.3 Less commonly (approximately 5% of cases), t(21;22) (EWSR1/ERG fusion) is found in these tumors.3 Rhabdomyosarcomas are another pediatric sarcoma associated with characteristic translocations. Most cases of alveolar rhabdomyosarcomas will have a t(2;13), which results in a PAX3/FOXO1A gene fusion and is associated with poor prognosis. More rarely, t(1;13) is found in alveolar rhabdomyosarcomas. Embryonal rhabdomyosarcomas do not display a characteristic translocation but are associated with abnormalities of chromosome 11p.

Wilms tumor is the most common renal tumor of childhood. The Wilms tumor-associated gene (WT1) is located at 11p13. Both deletions and translocations involving this gene are associated with the neoplasm. However, these abnormalities are more frequently seen in syndromic cases. Only 10% of sporadic Wilms tumors contain a WT1 mutation.4 A second gene (WT2) has been identified at 11p15. Other chromosomal abnormalities more rarely associated with Wilms tumor include deletions of 1p and 16q, gains of 1q, and loss of 22.5

The cytogenetic abnormalities of many frequent pediatric solid tissue tumors are characteristic and well studied. Detection of a characteristic abnormality can aid in diagnosis as well as predict prognosis in many instances. Even in light of new molecular methods, the role of cytogenetics in pediatric neoplasia continues to be vitally important.

References

  1. Stastny, P. Polymorphism and antigenicity of HLA-MICA. ASHI Quarterly. Second Quarter 2002:64–65.
  2. Betts DR, Cohen N, Leibundgut KE, et al. Characterization of karyotypic events and evolution in neuroblastoma. Pediatric blood and cancer. 2005; 44(2):147–157.
  3. Unni KK, Inwards CY, Bridge JA, Kindblom L-G, Wold LE. “Ewing’s Sarcoma” in AFIP Atlas of Tumor Pathology: Tumors of the Bones and Joints, Series IV. Washington, D.C.: ARP Press; 2005: 209–222.
  4. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. American Journal of Surgical Pathology. 2005; 29(8):1025–1033.
  5. Murphy WM, Grignon DJ, Perlman EJ. “Wilms Tumor” in AFIP Atlas of Tumor Pathology: Tumors of the Kidney, Bladder, and Related Urinary Structures, Series IV. Washington, D.C.: ARP Press; 2005: 10–38.
  6. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. children’s cancer study group. Medical and Pediatric Oncology. 2002; 38(1):11–21.

Download this article in Microsoft Word format.
Download this article in PDF format.


NewsPath® Editor: C. Leilani Valdes, MD
This newsletter is produced in cooperation with the College of American Pathologists Public Affairs Committee and the NewsPath Editorial Board and may be reproduced in whole or in part as a service to the medical community. Copyright © 2008 by the College of American Pathologists.
Please e-mail any comments to newspath@cap.org.

 

Related Links

       
 
 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed